



I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202, on February 24, 2003.

Frank C. Eisenschenk

Frank C. Eisenschenk, Ph.D., Patent Attorney

AMENDMENT UNDER
37 C.F.R. § 1.825(a)-(c)
Examining Group 1631
Patent Application
Docket No. GEN-T112XC1
Serial No. 09/326,402

#9 29/F

Plunk

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Channing Mahatan
Art Unit : 1631
Applicants : Marta Blumenfeld, Lydie Bougueleret, Ilya Chumakov
Serial No. : 09/326,402
Filed : June 4, 1999
Confirm. No. : 4132
For : Polymorphic Markers of Prostate Carcinoma Tumor Antigen-1 (PCTA-1)

BOX SEQUENCE
U.S. Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

AMENDMENT UNDER 37 C.F.R. §§ 1.825(a) THROUGH (c)

Sir:

Please amend the above-identified application as follows, in order to comply with the requirements of 37 C.F.R. § 1.821-1.825:

In the Specification

Please replace pages 1-148 of the Substitute Sequence Listing submitted to the Patent Office on October 31, 2001, with the accompanying Sequence Listing as new pages 1-157.